



A Year of Certification, Innovation and Commercial Acceleration



Dear Shareholders,

The year 2025 has been a decisive period for bonyf, marked by regulatory achievements, sustained innovation and accelerating commercial momentum. In an environment shaped by increasingly stringent European regulations and rising international standards, bonyf has reinforced its position as a compliant, innovation-driven medical device group.

MDR CERTIFICATION

In 2025, bonyf successfully maintained and strengthened its MDR certifications, ensuring uninterrupted access to the European medical device market. This achievement confirms the robustness of the Group's quality systems, clinical validation and post-market surveillance, and reinforces confidence among dental professionals and distribution partners.

PRODUCT INNOVATION

During 2025, bonyf advanced four key product developments:

- **PerioCream:** fully certified for professional periodontal care in Europe.
- **EfferWhite:** next-generation home whitening solution.
- **GumFix:** cosmetic product in certification phase.
- **NailFix:** cosmetic product in certification phase.

STRATEGIC PARTNERSHIP – INDIA

Cooperation with shareholder Group Pharmaceuticals entered its operational phase, with preparations underway for licensed production of selected bonyf products in India, supporting scalable manufacturing and market expansion while preserving Swiss quality and intellectual property.



COMMERCIAL EXPANSION

PerioCream achieved strong market uptake, with two major distribution contracts secured in the United States and Europe, validating bonyf's focus on high-end professional medical devices.

FINANCIAL PERFORMANCE AND DISCLOSURE POLICY

For the 2025 financial year, bonyf AG the Liechtenstein company exporting worldwide realized a 6.7% increase in turnover, reaching EUR 3,551,000. These figures do not include Belgian holding bonyf NV revenues of EUR 329,000. A substantial order backlog exists, not included in these figures, and expected to be realized in subsequent periods.

As a listed company on Euronext Access Paris, bonyf NV will disclose only its own statutory financial statements. Consolidated group figures will not be published at this stage in order to avoid significant costs related to full consolidated reporting requirements.

OUTLOOK

With MDR compliance secured, expanding industrial partnerships and a growing portfolio of innovative products, bonyf enters 2026 with confidence and a solid foundation for scalable international growth.

We sincerely thank our shareholders for their continued trust and support.

*Jean-Pierre Bogaert
Chairman & CEO – bonyf NV*

Letter to Shareholders – January 2026

QUOTATION & IDENTIFICATION

LISTING MARKET:
EURONEXT GROWTH ACCESS

ISIN CODE:
BE6333353298

MNEMONIC CODE:
MLBON

**MARKET CAPITALISATION ON
30/11/2022:**
€ 7,063,200

CONTACT

bonyf NV
Jean-Pierre Bogaert
Founder and Chief Executive Officer
president@bonyf.com